Opinion|Videos|October 25, 2024
Timing and Urgency Considerations in SCLC
Key Takeaways
- Early initiation of immunotherapy in SCLC, often with chemotherapy, maximizes therapeutic benefits and leverages potential synergistic effects.
- Inpatient versus outpatient immunotherapy administration depends on patient stability, treatment complexity, and resource availability.
Panelists discuss how to determine the optimal timing for initiating immunotherapy in patients with small cell lung cancer (SCLC), considering the pros and cons of inpatient vs outpatient administration, while also addressing the unique barriers to diagnosing and treating SCLC compared with non–small cell lung cancer and exploring strategies to overcome these challenges.
Advertisement
Episodes in this series
What is optimal timing for starting immunotherapy in patients with small cell lung cancer (SCLC)? What are the considerations when deciding on whether to administer immunotherapy in the inpatient or outpatient setting?
What are barriers to diagnosing and treating SCLC compared with non– small cell lung cancer, and how can they be overcome?
Advertisement
Related to this article
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
These findings demonstrate substantial but variable use of community care consultations for specialty care among patients with diabetic foot ulcers within the Veterans Health Administration.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
3
Switching to Subcutaneous Ocrelizumab for MS Could Free 883 Chair Hours in a Year
4
Why 4 in 5 Eligible Adults Miss Lung Cancer Screening
5